Q2 2025 · 13F-HR
BIOS Capital Management, LPholdings as filed
Filed 2025-08-12 · accession 0001104659-25-076893
$72.6M
Reported value
6
Positions
2025-06-30
Period end
The Brief · BIOS Capital Management, LP · Q2 2025
AI · grounded in 13F
BIOS Capital Management, LP established a new position in ACTU valued at $60.89M. The fund also opened new stakes in IRD for $3.46M and LTRN for $3.4M. Additional new positions include RNTX, CGTX, and INABEUR.
Holdings as filed
| CUSIP | Ticker | Issuer | Value | % port. | Shares | Class | Voting |
|---|---|---|---|---|---|---|---|
| 005083100 | ACTU | ACTUATE THERAPEUTICS INC | $60.9M | 83.9% | 9,965,079 | Common | SHARED |
| 67577R102 | IRD | OPUS GENETICS INC | $3.5M | 4.77% | 3,683,429 | Common | SHARED |
| 51654W101 | LTRN | LANTERN PHARMA INC | $3.4M | 4.68% | 1,075,952 | Common | SHARED |
| 00887A204 | RNTX | REIN THERAPEUTICS INC | $2.4M | 3.26% | 1,690,751 | Common | SHARED |
| 19243B102 | CGTX | COGNITION THERAPEUTICS INC | $1.9M | 2.56% | 6,000,000 | Common | SHARED |
| 45674E109 | INABEUR | IN8BIO INC | $599,128 | 0.83% | 286,664 | Common | SHARED |
Source: SEC EDGAR · raw 13F holdings as filed. The Class column shows the option type when reported (Put/Call) or Common when the issuer's equity is held directly. 13F discloses long positions only.